Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Bar-Or A, Calabresi PAJ, Arnold D, Arnlod D, Markowitz C, Shafer S, Kasper LH, Waubant E, Gazda S, Fox RJ, et al. Ann Neurol. 2008 Mar; 63(3):395-400. PMID: 18383069. Abstract CommentRecommendBookmarkWatch